Dr. Zhang Yongchang is an associate chief physician, professor, and honorary professor at Central South University and Hunan Normal University. He currently serves as the director of the Early Clinical Research Center and the Anticancer New Drug Research Ward at Hunan Provincial Cancer Hospital. Additionally, he is the deputy chief of the Lung-Gastrointestinal Internal Medicine Department and the director of the Hunan Provincial Key Laboratory of Precision Diagnosis and Treatment for Lung Cancer. Dr. Zhang specializes in the precision diagnosis and treatment of malignant tumors and the development of new drugs, with significant contributions to the clinical treatment and translational research of lung cancer. Over the past five years, Dr. Zhang has published over 100 peer-reviewed papers in leading oncology journals. Dr. Zhang has been funded by the National Natural Science Foundation of China for Outstanding Young Scientists and has been recognized as a leading talent in Science and Technology Innovation in Hunan Province. Dr. Zhang's primary research focuses on clinical studies of new anticancer drugs, with a specific emphasis on targeted therapy and immune resistance in lung cancer and gastrointestinal malignancies. He has led more than 10 IND studies, including Phase I-IV clinical trials of new drugs, as well as studies on novel cell immunotherapy, BE/PK, and healthy subjects. He excels in clinical trials of novel anticancer drugs, including new immune checkpoint inhibitors, novel ADC drugs, cell immunotherapy (CART, TILs), and tumor vaccines. His dedication to finding a cure for advanced malignant tumors brings hope to patients. Dr. Zhang serves as a standing committee member of the Integrated Rehabilitation Committee for Bone and Soft Tissue Tumors of the Chinese Anti-Cancer Association, a member of the Oncology Respiratory Disease/Oncology Precision Treatment Committee of the Chinese Anti-Cancer Association, and a member of the Palliative Care/Malignant Mesothelioma Committee of the Chinese Anti-Cancer Association. He is also a council member of the Young Scientists Association in Hunan Province, chairman of the Young Committee of the Precision Medicine Professional Committee of the Hunan Province Anti-Cancer Association, and vice chairman of the Young Committee of the Oncology Internal Medicine Professional Committee of the Hunan Medical Association. Dr. Yang Nong is the vice president of the Second People's Hospital of Hunan Province, China. He is a chief physician and a doctoral supervisor. Additionally, he holds positions as a long-term expert at Hainan Cancer Hospital, Hainan Chengmei Hospital, and Hainan Tropical Cancer Research Institute. He also serves as the director of the Hunan Province Clinical Medical Research Center for Respiratory Cancer, the director of the Key Laboratory for Precision Diagnosis and Treatment of Lung Cancer, and a chief expert of the National Science and Technology Major Project. Furthermore, he acts as an evaluation expert for the Center for Drug Evaluation (CDE) under the National Medical Products Administration of China. In 2022, Dr. Yang was included in the Top 100 Scholars List for Academic Influence in Chinese Lung Cancer Research (ranked 54th), and in 2020, he was ranked 12th in terms of academic influence in Chinese lung cancer research. Dr. Yang specializes in precise immunotherapy, targeted therapy, and chemotherapy for lung and gastrointestinal cancers. He has accumulated a wealth of successful cases in these areas, particularly in dealing with complex and drug-resistant cases. His research focuses on precise immunotherapy, targeted therapy, and chemotherapy for lung and gastrointestinal cancers. Dr. Yang has contributed to the development of several clinical guidelines and consensus reports, including those of the Chinese Society of Clinical Oncology and the Chinese Medical Association. He has been involved in the formulation of guidelines for clinical trials conducted by the CDE for multiple anti-cancer drugs. As the principal investigator or leading PI, he has designed, organized, and participated in nearly 400 phase I-III clinical trials, with over 40 ongoing clinical studies. Over the past five years, Dr. Yang has published more than 43 academic papers and the total impact factor of these papers exceeds 375.23. Notably, his research has revealed the molecular mechanisms of primary resistance to ALK fusion lung cancer targeted therapy, specifically the fusion of reciprocal and non-reciprocal ALK partners. This achievement has been incorporated into the Chinese Society of Clinical Oncology's consensus interpretation of testing reports, and he was invited to contribute to the ASCO ALK Fusion Lung Cancer Testing Guidelines.
